Evolution of the mCRPC treatment landscape

A new article by Jeffress in the cancer business publication OBR Green discusses the changing patterns of use of  the various approved drugs in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

No decrease in mortality rate of newly diagnosed men with metastatic prostate cancer

A newly published paper in the journal Cancer has indicated that, here in the USA, although overall prostate cancer mortality has declined by ~ 40 percent during the past 25 years, there has been no significant decrease in the mortality rate among men who have evident metastatic prostate cancer at time of diagnosis. … READ MORE …

Repeat biopsies may (or may not) be important for patients on AS — even when PSA is stable

A new report based on data from the cohort of patients being managed with active surveillance (AS) at the University of California, San Francisco, has emphasized the potential importance of repeat biopsies in the care and treatment of these men. … READ MORE …

Changing physicians’ behaviors (about PSA testing)

It is common for patients to suggest that primary care physicians should be more knowledgeable about the appropriate use of PSA testing and about how to interpret the results of such tests. However, changing physician behavior is not an easy or a quick process, as the following article will demonstrate. … READ MORE …